Advertisement

Alzheimer's Researcher Pushes Forward With Immunotherapy Trials Despite Setbacks In The Field

06:55
Download Audio
Resume
R. Scott Turner, professor of neurology and director of the Memory Disorder Center at Georgetown University Hospital, points to PET scan results that are part of a study on Allheimer's disease on May 19, 2015, in Washington. (Evan Vucci/AP)
R. Scott Turner, professor of neurology and director of the Memory Disorder Center at Georgetown University Hospital, points to PET scan results that are part of a study on Allheimer's disease on May 19, 2015, in Washington. (Evan Vucci/AP)

For two decades, scientists have been studying how immunotherapies may help treat Alzheimer's disease. The theory is that antibodies might trigger the brain to destroy a kind of protein that clumps in the brain of patients. The clumps are known as beta-amyloid plaques.

Recently, some large clinical trials of that kind of immunotherapy have failed.
An editorial in the New England Journal of Medicine says researchers may be "nearing the end of the amyloid-hypothesis rope."

Dr. Reisa Sperling says not yet, and she speaks with Here & Now's Lisa Mullins.

This segment aired on February 13, 2018.

Related:

Advertisement

More from Here & Now

Listen Live
Close